Botanix Pharmaceuticals Limited
BXPHF
$0.04
$0.0010.88%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4,303.82% | 4,168.38% | 210.96% | 205.18% | -0.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4,303.82% | 4,168.38% | 210.96% | 205.18% | -0.16% |
| Cost of Revenue | 396.67% | 381.53% | -6.83% | -8.56% | 23.53% |
| Gross Profit | 1,378.03% | 1,339.19% | 381.87% | 376.63% | -38.45% |
| SG&A Expenses | 44.19% | 39.78% | 589.82% | 576.89% | 510.45% |
| Depreciation & Amortization | 6.86% | 3.60% | 1,639.34% | 1,603.32% | 13,392.59% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.07% | 51.30% | 439.35% | 429.24% | 447.84% |
| Operating Income | -5.91% | -2.67% | -484.97% | -474.03% | -478.46% |
| Income Before Tax | -8.25% | -4.94% | -542.17% | -530.15% | -464.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.25% | -4.94% | -542.17% | -530.15% | -464.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.25% | -4.94% | -542.17% | -530.15% | -464.91% |
| EBIT | -5.91% | -2.67% | -484.97% | -474.03% | -478.46% |
| EBITDA | -5.88% | -2.64% | -476.19% | -465.40% | -459.10% |
| EPS Basic | 0.00% | 3.51% | -427.78% | -416.67% | -358.33% |
| Normalized Basic EPS | 0.00% | 2.78% | -436.36% | -427.27% | -337.50% |
| EPS Diluted | 0.00% | 3.51% | -427.78% | -416.67% | -358.33% |
| Normalized Diluted EPS | 0.00% | 2.78% | -436.36% | -427.27% | -337.50% |
| Average Basic Shares Outstanding | 8.11% | 8.11% | 19.73% | 19.73% | 26.29% |
| Average Diluted Shares Outstanding | 8.11% | 8.11% | 19.73% | 19.73% | 26.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |